Blanca Acha

Blanca Acha

Auto-generated profile, based on publicly available information

Blanca Acha

From the Navarrabiomed (B.A., J.S.-R.d.G., C.C., M. Robles, I.M.-L., M.M., S.Z., M. Roldan, A.U.-C., I.J., M.E.E., I.B.-L., M.M.), Hospital Universitario de Navarra-IdiSNA (Navarra Institute for Health Research), Universidad Pública de Navarra (UPNA); Departments of Neurology (J.C., J.S.-R.d.G., C.C., I.J., M.E.E., M.M.) and Internal Medicine (I.M.-L.), Hospital Universitario de Navarra-IdiSNA (Navarra Institute for Health Research), Pamplona; Department of Neurology (D.A., A.L.), Institut...

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2020 in Epigenetics
Verified
Journal Article
Closed access
IBIdoia Blanco-Luquin
Idoia Blanco-Luquin
BABlanca Acha
Blanca Acha
ACAmaya Urdánoz Casado
Amaya Urdánoz Casado
JSJavier Sánchez
Javier Sánchez
JVJanire Vicuña-Urriza
Janire Vicuña-Urriza
MMMaite Mendioroz
Maite Mendioroz
The discovery of new biomarkers would be very valuable to improve the detection of early Alzheimer’s disease (AD). DNA methylation marks may serve as epigenetic biomarkers of early AD. Here we identified epigenetic marks that are present in the human hippocampus from the earliest stages of AD. A previous methylome dataset of the human AD hippocampus was used to select a set of 8 differentially methylated positions (DMPs) since early AD stages. Next, bisulfite pyrosequencing was performed in an expanded homogeneous cohort of 18 pure controls and 35 hippocampal samples with neuropathological changes of pure AD. Correlation between DNA methylation levels in DMPs and phospho-tau protein burden assessed by immunohistochemistry in the hippocampus was also determined. We found 4 DMPs showing higher levels of DNA methylation at early AD stages compared to controls, involving ELOVL2, GIT1/TP53I13 and the histone gene locus at chromosome 6. DNA methylation levels assessed by bisulfite pyrosequencing correlated with phospho-tau protein burden for ELOVL2 and HIST1H3E/HIST1H3F genes. In this discovery study a set of 4 epigenetic marks of early AD stages have been identified in the human hippocampus. These epigenetic changes point to specific pathways that might be involved in AD pathogenesis, such as the long-chain fatty acid biogenesis or histone functions. It would be worth studying in depth the specific pathways related to these epigenetic marks. These early alterations in DNA methylation in the AD hippocampus could be regarded as candidate biomarkers to be explored in future translational studies.

5 December 2023 in Neurology
Verified
Journal Article
Open access
PDF file
BABlanca Acha
Blanca Acha
JCJon Corroza
Jon Corroza
JSJavier Sánchez
Javier Sánchez
CCCAROLINA CABELLO
CAROLINA CABELLO
MRMaitane Robles
Maitane Robles
FGfor the iBEAS Study Group
for the iBEAS Study Group
Background and Objectives There is an urgent need to identify novel noninvasive biomarkers for Alzheimer disease (AD) diagnosis. Recent advances in blood-based measurements of phosphorylated tau (pTau) species are promising but still insufficient to address clinical needs. Epigenetics has been shown to be helpful to better understand AD pathogenesis. Epigenetic biomarkers have been successfully implemented in other medical disciplines, such as oncology. The objective of this study was to explore the diagnostic accuracy of a blood-based DNA methylation marker panel as a noninvasive tool to identify patients with late-onset Alzheimer compared with age-matched controls. Methods A case-control study was performed. Blood DNA methylation levels at 46 cytosine-guanine sites (21 genes selected after a comprehensive literature search) were measured by bisulfite pyrosequencing in patients with “probable AD dementia” following National Institute on Aging and the Alzheimer9s Association guidelines (2011) and age-matched and sex-matched controls recruited at Neurology Department-University Hospital of Navarre, Spain, selected by convenience sampling. Plasma pTau181 levels were determined by Simoa technology. Multivariable logistic regression analysis was performed to explore the optimal model to discriminate patients with AD from controls. Furthermore, we performed a stratified analysis by sex. Results The final study cohort consisted of 80 patients with AD (age: median [interquartile range] 79 [11] years; 58.8% female) and 100 cognitively healthy controls (age 77 [10] years; 58% female). A panel including DNA methylation levels at NXN, ABCA7, and HOXA3 genes and plasma pTau181 significantly improved (area under the receiver operating characteristic curve 0.93, 95% CI 0.89–0.97) the diagnostic performance of a single pTau181-based model, adjusted for age, sex, and APOE ɛ4 genotype. The sensitivity and specificity of this panel were 83.30% and 90.00%, respectively. After sex-stratified analysis, HOXA3 DNA methylation levels showed consistent association with AD. Discussion These results highlight the potential translational value of blood-based DNA methylation biomarkers for noninvasive diagnosis of AD. Registration Information Research Ethics Committee of the University Hospital of Navarre (PI17/02218).

22 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
IBIdoia Blanco-Luquin
Idoia Blanco-Luquin
BABlanca Acha
Blanca Acha
ACAmaya Urdánoz Casado
Amaya Urdánoz Casado
EGEva Gomez-Orte
Eva Gomez-Orte
MRMiren Roldán
Miren Roldán
MMMaite Mendioroz
Maite Mendioroz
In view of the proven link between adult hippocampal neurogenesis (AHN) and learning and memory impairment, we generated a straightforward adult neurogenesis in vitro model to recapitulate DNA methylation marks in the context of Alzheimer’s disease (AD). Neural progenitor cells (NPCs) were differentiated for 29 days and Aβ peptide 1–42 was added. mRNA expression of Neuronal Differentiation 1 (NEUROD1), Neural Cell Adhesion Molecule 1 (NCAM1), Tubulin Beta 3 Class III (TUBB3), RNA Binding Fox-1 Homolog 3 (RBFOX3), Calbindin 1 (CALB1), and Glial Fibrillary Acidic Protein (GFAP) was determined by RT-qPCR to characterize the culture and framed within the multistep process of AHN. Hippocampal DNA methylation marks previously identified in Contactin-Associated Protein 1 (CNTNAP1), SEPT5-GP1BB Readthrough (SEPT5-GP1BB), T-Box Transcription Factor 5 (TBX5), and Nucleoredoxin (NXN) genes were profiled by bisulfite pyrosequencing or bisulfite cloning sequencing; mRNA expression was also measured. NXN outlined a peak of DNA methylation overlapping type 3 neuroblasts. Aβ-treated NPCs showed transient decreases of mRNA expression for SEPT5-GP1BB and NXN on day 9 or 19 and an increase in DNA methylation on day 29 for NXN. NXN and SEPT5-GP1BB may reflect alterations detected in the brain of AD human patients, broadening our understanding of this disease.

24 November 2025 in bioRxiv
Verified
Preprint
Open access
IBIdoia Blanco-Luquin
Idoia Blanco-Luquin
MMMónica Macías
Mónica Macías
IMIbai Marro
Ibai Marro
MPMarta Puebla-Guedea
Marta Puebla-Guedea
BABlanca Acha
Blanca Acha
MMMaite Mendioroz
Maite Mendioroz
Background: Mindfulness meditation has gained significant attention in the context of Alzheimer’s disease (AD) due to its potential effects on the prevention of cognitive decline and overall psychological well-being. The epigenetic landscape of this complex neurodegenerative disorder can be influenced by environmental factors. Mindfulness practices could actively shape the biological response to AD by modifying the underlying molecular mechanisms through epigenetic regulation. Methods: A group of 17 long-term mindfulness meditators (MMs) and 17 sex- and age-matched controls were recruited. Experienced MMs participated in a 1-month Vipassana meditation retreat. Blood DNA methylation levels of differentially methylated genes ( ABCA7, ADAM10, APOE, HOXA3, NXN, TREM2 and TREML2 ) previously validated in a predictive AD-model found analyzed by bisulfite pyrosequencing. Results: An increase in DNA methylation was observed for ADAM10, APOE, HOXA3 and TREM2 in MMs with respect to controls. Furthermore, significant differences were found for ABCA7, ADAM10, APOE and HOXA3 in MMs after retreat. Conclusions: DNA methylation changes identified for ADAM10 and HOXA3 in MMs are in the opposite direction to those occurring in AD and may constitute a protective epigenetic alteration. Mindfulness practice could counteract DNA methylation of key AD genes as a possible preventive strategy or non-pharmacological intervention in AD patients.

6 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
IBIdoia Blanco-Luquin
Idoia Blanco-Luquin
JCJuan Cabello
Juan Cabello
ACAmaya Urdánoz Casado
Amaya Urdánoz Casado
BABlanca Acha
Blanca Acha
EGEva Gomez-Orte
Eva Gomez-Orte
MMMaite Mendioroz
Maite Mendioroz
Adult hippocampal neurogenesis (AHN) study is still a challenge. In addition to methodological difficulties is the controversy of results derived of human or animal system approaches. In view of the proven link between AHN and learning and memory impairment, we generated a straightforward in vitro model to recapitulate adult neurogenesis in the context of Alzheimer’s disease (AD). Neural progenitor cells (NPCs) monolayer culture was differentiated for a period of 29 days and Aβ peptide 1-42 was administered once a week. mRNA expression of NEUROD1, NCAM1, TUBB3, RBFOX3, CALB1 and GFAP genes was determined by RT-qPCR. Phenotypic changes were observed during directed differentiation. Except for GFAP and CALB1 , these changes correlated with altered expression profile of all genes since 9 days. Only TUBB3 expression remained constant while NEUROD1, NCAM1 and RBFOX3 expression increased over time. Moreover, Aβ treated NPCs showed transient decreases of mRNA expression for NCAM1, TUBB3 and RBFOX3 genes at 9 or 19 days. Our in vitro human NPCs model is framed within the multistep process of AHN in the SGZ of the DG. Remarkably, its transcriptional assessment might reflect alterations detected in AD human patients, deepening our understanding of the disorder and possibly of its pathogenesis. SUMMARY STATEMENT: Transcriptional profile of a number of genes recapitulating particular stages of Adult hippocampal neurogenesis in the context of Alzheimer’s disease

2 April 2024
Verified
Thesis
Closed access
BSBlanca Acha Santamaría
Blanca Acha Santamaría
En esta tesis doctoral, se investiga el papel de la metilación del DNA como un potencial biomarcador diagnóstico de la EA, dada la novedad que los mecanismos epigenéticos han supuesto en la búsqueda de biomarcadores en la última década. Para su desarrollo, se plantea una aproximación de gen candidato. Tras una extensa revisión bibliográfica, se seleccionaron 21 genes candidatos, cuyos niveles de metilación del DNA se midieron mediante la técnica de pirosecuencación por bisulfito en un grupo de 80 pacientes con EA y 100 controles. El análisis estadístico identificó 11 posiciones (CpGs) de metilación diferencial entre pacientes y controles. Con estos resultados se construyó un modelo de regresión logística multivariable que incluyó las posiciones diferencialmente metiladas (Differentially Methylated Positions, DMPs) identificadas en los genes NXN, TREML2, ABCA7 y HOXA3, cuya capacidad de discriminación de pacientes con EA fue del 87%. La construcción de un modelo de regresión logística donde se combinaron las marcas de metilación del DNA y pTau181 plasmático, con una capacidad de discriminación del 93%, mejoró la capacidad diagnóstica de pTau181 plasmático (85%), considerada la herramienta diagnóstica plasmática más promotedora hasta la fecha. El sexo y el genotipo APOE son, junto con la edad, los principales factores de riesgo (FR) de la EA, por lo que se estudió su asociación con las marcas de metilación del DNA identificadas en este estudio. Se encontraron marcas de metilación del DNA diferenciales entre pacientes con EA y controles en función del sexo y del genotipo APOE. Curiosamente, los niveles de metilación de la CpG localizada en el gen HOXA3 Chr7:27153577 mostraron diferencias estadísticamente significativas entre pacientes con EA y controles en la cohorte global y en todos los grupos tras la estratificación por sexo y genotipo APOE. Además, también mostraron correlación con la variable que refleja el estado cognitivo, el MMSE, y con los niveles de pTau181 plasmático, postulándose como una herramienta prometedora en la mejora de la precisión diagnóstica de la EA como parte de un panel de biomarcadores en sangre periférica. A su vez, las DMPs localizadas en los genes IRS2, HAND2 y RHBDF2 correlacionaron con los niveles de los biomarcadores core de líquido cefalorraquídeo (LCR) en los pacientes con EA de nuestra cohorte iBEAS, sin ser validados en una cohorte externa cedida por el Hospital Sant Pau (Barcelona). Como conclusión, este trabajo muestra la existencia de marcas de metilación del DNA en la sangre como potenciales herramientas en la mejora de la capacidad diagnóstica en la EA, ntegrados en paneles de biomarcadores periféricos. Además, estos resultados apoyan la posible implicación de la metilación del DNA en la patología de la EA.